Zhang Ge, Mi Wunan, Wang Chuyue, Li Jiehan, Zhang Yizheng, Liu Nannan, Jiang Meimei, Jia Guiyun, Wang Feng, Yang Ge, Zhang Lingling, Wang Jiangang, Fu Yang, Zhang Yingjie
Department of Health Management, The Third Xiangya Hospital, Central South University, Changsha, China.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Cell Death Discov. 2023 Dec 15;9(1):457. doi: 10.1038/s41420-023-01746-x.
Ferroptosis is a new type of iron-dependent programmed cell death induced by lipid peroxidation. However, the underlying mechanisms and function in tumor therapy still remain undisclosed especially in post-transcription regulation. Here, we found that targeting AKT significantly induced GPX4 dependent ferroptosis and suppressed colorectal cancer growth both in vitro and in vivo. During this process, demethylase FTO was downregulated, which increased the m6A methylation level of GPX4, subsequently recognized by YTHDF2 and degraded. Prediction results showed that there are three potential methylated sites (193/647/766), and 193 site was identified as the right one, which was demethylated by FTO and read by YTHDF2. In parallel, AKT inhibition caused the accumulation of ROS which had a negative feedback on GPX4 expression. In addition, protective autophagy was initiated by MK2206 stimulation, while blocking autophagy further increased ferroptosis and markedly enhanced the anti-tumor activity of MK2206. In a word, inhibiting AKT activated ferroptosis through FTO/YTHDF2/GPX4 axis to suppress colon cancer progression, which raised FTO/GPX4 as potential biomarkers and targets in colorectal cancer therapy.
铁死亡是一种由脂质过氧化诱导的新型铁依赖性程序性细胞死亡。然而,其潜在机制以及在肿瘤治疗中的作用仍未明确,尤其是在转录后调控方面。在此,我们发现靶向AKT可显著诱导GPX4依赖性铁死亡,并在体外和体内抑制结直肠癌的生长。在此过程中,去甲基化酶FTO下调,这增加了GPX4的m6A甲基化水平,随后被YTHDF2识别并降解。预测结果显示存在三个潜在的甲基化位点(193/647/766),且确定193位点为正确位点,其被FTO去甲基化并被YTHDF2识别。同时,AKT抑制导致ROS积累,这对GPX4表达产生负反馈。此外,MK2206刺激引发保护性自噬,而阻断自噬可进一步增加铁死亡并显著增强MK2206的抗肿瘤活性。总之,抑制AKT通过FTO/YTHDF2/GPX4轴激活铁死亡以抑制结肠癌进展,这使FTO/GPX4成为结直肠癌治疗中的潜在生物标志物和靶点。